Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

In particular, the third quarter of the fiscal year also saw record revenue and margins, with the gross margin improving by 1.6 percentage points from 58.7% to 60.3%. The company's UGG and Hoka brands ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) yesterday and set a price ...

The S&P 500 (SP500) hit new highs during February trade, but that wasn’t enough to stave off a monthly loss. The benchmark ...

Corneal Ulcer Treatment MarketThe global corneal ulcer treatment market is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching a market value of USD 1,601.1 million by 2034. In 2024, the ...

In this report the analyst provides an in-depth analysis of the key themes, strategic moves, and market dynamics presented at the conference, offering insights into how major players are positioning ...